Navigation Links
VirtualScopics to Present at the 14th Annual BIO CEO & Investor Conference
Date:2/10/2012

ROCHESTER, N.Y., Feb. 10, 2012 /PRNewswire/ -- VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of quantitative imaging for clinical trials, announced today that Mr. Jeff Markin, the company's president and chief executive officer, will be presenting a corporate overview at the upcoming 14th Annual BIO CEO & Investor Conference at the Waldorf Astoria in New York City. Mr. Markin's presentation will be on Monday, February 13, 2012 at 4:30 PM ET.

A live webcast of the presentation will be available for 30 days in the Investor Relations section of the company's website, www.virtualscopics.com.

About VirtualScopics, Inc.VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development.  VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images.  In combination with VirtualScopics' industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster.  For more information about VirtualScopics, visit www.virtualscopics.com.

Forward-Looking Statements

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Company's investment in infrastructure and new cu
'/>"/>

SOURCE VirtualScopics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. VirtualScopics Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial
2. VirtualScopics Project Balance Exceeds a Record $35 Million
3. VirtualScopics to Present at the 8th Annual Bio Investor Forum
4. VirtualScopics Schedules Third Quarter 2009 Earnings Announcement
5. VirtualScopics to Present at the Upcoming OneMedPlace Investment Conference
6. VirtualScopics Receives Issuance in Japan of Prominent Patent
7. VirtualScopics Added to Russell Microcap Index
8. VirtualScopics Schedules Second Quarter 2010 Earnings Announcement
9. VirtualScopics and ABX-CRO Collaborate to Enhance Global Molecular Imaging Offerings
10. VirtualScopics to Present at the Upcoming Rodman & Renshaw Annual Global Investment Conference
11. VirtualScopics Revenues Hit Another Quarterly Record
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Luoxis Diagnostics, Inc. , a ... MKT: AMPE), today announced an upcoming presentation at ... American Academy of Surgical Trauma (AAST) and Clinical ... Philadelphia, Pennsylvania that will be held ... from a recently completed five-year prospective clinical trial ...
(Date:8/19/2014)... , August 19, 2014 ,Weight ... Pipeline Assessment, 2014, report provides comprehensive insights about phase ... A key objective of the report is to establish ... III pipeline drugs across the different countries and regions. ... thoroughly, the report also provides details on the drug ...
(Date:8/18/2014)... Gamida Cell , a world ... today that it has signed an investment and option agreement ... Novartis " ) . According to the agreement, ... return will receive 15% equity and an option to fully ... period of time following achievement of certain milestones connected to ...
Breaking Medicine Technology:Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 3Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 2Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 3Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 4Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 2Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 3Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 4
... - Both co-primary endpoints, Wake After Sleep Onset and ... Sleep, were met at both doses - Evotec to ... 10am EST) today , HAMBURG, Germany | OXFORD, England, ... today positive top-line,results from its first phase II clinical ...
... Summary: Follow-up RAS data presented at ASCO , ... gave,a presentation titled "RAS peptide vaccination in resected,pancreatic ... long term survival" at ASCO's (American Society of ... of 23 resected pancreatic cancer patients,immunized in the ...
Cached Medicine Technology:Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 2Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 3Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 4Pharmexa A/S (DK) - Long lasting immune response and survival to,RAS vaccine 2
(Date:8/20/2014)... “Have you recently been involved in an auto ... lawyer serving the greater Seattle area. “Are you still feeling ... keep reading . , In a recently released article, Dax ... accident can use to see if they may qualify for ... insurance claim will allow an individual to receive medical treatment ...
(Date:8/20/2014)... August 20, 2014 Low market concentration, ... availability of substitutes typify the market for packaging design ... 3.1 out of 5, indicating a moderate level of ... and suppliers have an equal amount of leverage during ... , First, few substitutes exist for packaging design ...
(Date:8/20/2014)... First Choice Emergency Room , the ... United States, named Richard Daniels, DO the Medical Director ... , “We are pleased to announce that Dr. Daniels ... facility in Pflugerville,” said Dr. James M. Muzzarelli, Executive ... Dr. Daniels received his undergraduate degree from Brigham Young ...
(Date:8/20/2014)... 2014 Kowa Optimed returns after a ... debut the new SL-17 portable slit lamp. , The ... LED source controlled by an illuminated thumb wheel for ... uses commercially available AAA rechargeable and dry cell batteries, ... requiring batteries designed specifically for the device. The new ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 This ... line of software defined networking, high availability cloud ... portfolio of Resellers, while allowing OPEN-V to sell ... is pleased to work with OPEN-V on this ... Donald Hows, manager distribution channels at storageFOUNDRY. "Nautilus ...
Breaking Medicine News(10 mins):Health News:Five Questions to Determine Who Qualifies for a Personal Injury Claim Recently Released by The Jones Firm in Recent Article 2Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 2Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 3Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 4Health News:First Choice Emergency Room Announces Dr. Richard Daniels as Medical Director of the Pflugerville – FM 685 Facility 2Health News:Kowa Optimed (Booth MS13043) to Debut New Portable Slit Lamp at 2014 Vision Expo West in Las Vegas, Nevada 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 3
... , TUESDAY, Oct. 11 (HealthDay News) -- A small, preliminary study ... intestines -- a potential sign that the pills might reduce the ... be done, and the researchers aren,t yet recommending that people head ... meal times. "If you want to add ginger to part ...
... Goodwin HealthDay Reporter , TUESDAY, Oct. 11 (HealthDay ... raises the risk for both breast and ovarian cancer are ... new study indicates. Those other women include both women ... of breast and ovarian cancer, and women without ...
... A team of scientists led by a Penn State ... an alternative method of molecular depth profiling -- a ... such as human tissue, nanoparticles, and other substances. In ... modeling to show the effectiveness and limitations of the ...
... is exploring the ethical challenges that clinicians and ... in the United States. The project is supported by ... Program. Most of the estimated 11 million undocumented ... are ineligible for public insurance programs. They are prohibited ...
... intersection density and well-connected streets in towns and cities ... according to a Queen,s University study. "We,ve known ... a high density of intersections in a given areahelps ... and more efficient for them to walk to work ...
... TUESDAY, Oct. 11 (HealthDay News) -- Nearly 90 percent of ... well-being, according to a new national poll of 1,000 voters. ... also revealed that by having routine mammograms, women gain a ... that poll results show that nearly nine in 10 women ...
Cached Medicine News:Health News:Ginger Supplements Might Ease Inflammation Linked to Colon Cancer 2Health News:Mutant Gene That Ups Risk for Ovarian Cancer May Aid Survival 2Health News:Mutant Gene That Ups Risk for Ovarian Cancer May Aid Survival 3Health News:Mutant Gene That Ups Risk for Ovarian Cancer May Aid Survival 4Health News:Molecular depth profiling modeled using buckyballs and low-energy argon 2Health News:Molecular depth profiling modeled using buckyballs and low-energy argon 3Health News:New project examines medical safety net for undocumented patients 2Health News:Women Say Mammograms Give Them Sense of Control: Survey 2
... MJS anatomic knee ... enhance durability, minimize polyethylene ... surfaces, to minimize contact ... and to achieve a ...
Simplified Design-Based on 15 Years of Experience...
... The result of more than a ... is based on a comprehensive study of ... resection, and tibial insert retrieval analysis.,As a ... axial rotation and motion patterns in total ...
... True to its leadership role within ... the clinical experience of the industry's leading ... Platform Knee System, with the clinically proven ... world's leading rotating platform knee. ,The result ...
Medicine Products: